Sir, Bevacizumab: a new way of doing business?
We wish to thank Franks for her insightful contribution to the debate on the indications and evidence for the use of bevacizumab in the eye.
One of the prerequisites for an ethical randomised controlled trial is the state of clinical equipoiseFthe researchers should not be biased strongly in favour of one treatment option or the other.
1 This implies a degree of uncertainty regarding the outcome for both treatment options.
Unfortunately there is little doubt about the natural history of rubeotic glaucoma unresponsive to laser. It is a dire condition with devastating consequences for the quality of the patient's life and their family. It is only natural to wish to do everything one can under such conditions. There is a good theoretical basis for the use of bevacizumab in this condition and so far the safety profile seems good.
We agree with Franks therefore that ranibizumab or bevacizumab in rubeotic glaucoma would be justified in the context of a carefully documented observational study. The wholesale use of this drug in a raft of conditions where other options exist remains a cause for comment. Bevacizumab might well be a very effective and cost-effective drug for much vascular eye pathologyFlet's just prove it! Retinal pigment epithelium (RPE) tear mostly occurs as a complication of age-related macular degeneration but may also develop as a rare complication after trauma.
1-5
Patients with traumatic RPE tear involving the fovea usually have poor visual prognosis. 1,2 We report the spontaneous resolution of traumatic RPE tears and pigment epithelial detachment (PED) in a patient after blunt trauma who subsequently had good visual recovery.
Case report
A 63-year-old woman presented with left blurred vision after being hit by a badminton racquet. Her left eye visual acuity was 20/30 and fundus examination revealed a 1.5 disc-diameter PED involving the fovea and a crescent-shaped lesion at the RPE level temporal to the fovea. Fluorescein angiography showed two areas of window defects due to RPE loss ( Figure 1 ) and optical coherence tomography (OCT) revealed two areas of RPE discontinuation within the PED (Figure 2a) . No rolling or retraction of the RPE was detected. She was managed conservatively and serial OCT showed progressive apposition of the torn RPE layer with reduction in PED (Figure 2b and c) . Six months later, her visual acuity recovered to 20/20 and OCT showed complete resolution of the PED and restoration of the normal retinal layers (Figure 2d ).
Comment
RPE tear occurs rarely after blunt trauma as the force causing the RPE tear falls in a very small window. 4 The force must be large enough to cause RPE tear but not too large in causing both RPE and Bruch's membrane tears as in choroidal rupture. As the elastic RPE tends to retract over the intact RPE, RPE tear is usually prevented from healing and visual recovery is generally poor. In our patient, OCT demonstrated no RPE retraction or rolling and spontaneous healing of the RPE tears could occur. This might be due to the development of two traumatic RPE tears, which have reduced the forces causing RPE retraction. Despite the PED and one of the traumatic RPE tears involving the fovea, her visual acuity recovered to 20/20. Our case illustrated that in the absence of RPE retraction, traumatic RPE tears may heal spontaneously and patients may have good final visual outcome. We report a patient with VPRT, who showed visual and clinical improvement after intravitreal Avastin.
Case report
A 59-year-old lady was referred in April 2006 with a right VPRT. She had been treated elsewhere with laser photocoagulation. Her general health was good apart from systemic hypertension. Examination showed right visual acuity of 6/6À1, and infero-temporal, pre-equatorial VPRT surrounded by hard exudates and old vitreous haemorrhage inferiorly (Figure 1 ). On ultrasonography, this tumour measured 5.0 mm in diameter and 1.7-mm thick (Figure 2) . The patient was treated with triple freeze-thaw cryotherapy. In June 2006, the visual acuity worsened to 6/19 due to cystoid macular oedema (Figure 3a) , and the tumour thickness increased to 2.6 mm. A decision was made to treat the patient with intraocular Avastin, 2.5 mg in 0.1 ml was administered in September 2006. Immediately after, the patient reported loss of sensation and weakness of her left arm and leg and was investigated for cerebrovascular accident, which was excluded. Five days later, the vision in the right eye had improved to 6/9 þ 3 and the macular oedema was no longer visible. Twenty-four days after treatment, the visual acuity was 6/6À1, tumour thickness 
